INTRODUCTION
Historically, research into the dopaminergic aspects of the mechanism of function of antipsychotic medications has focused on antagonism of the dopamine-2 (D 2 ) receptor (Creese et al, 1976; Seeman and Lee, 1975) . ) receptors belong to the same class of receptors as D 2 , and there is evidence they may have a role in several neuropsychiatric disorders, including addiction, Parkinson's disease, and schizophrenia (Sokoloff et al, 2006) . In particular, therapeutic agents targeted towards the D 3 receptor may hold promise as novel antipsychotic agents. Until recently, direct in vivo evidence of D 3 receptor dysfunction in neuropsychiatric populations has not been possible to obtain because of the lack of a positron emission tomography (PET) or single photon emission computed tomography (SPECT) imaging agent that can suitably distinguish between dopamine D 3 and D 2 binding. Hence, the potential contribution of D 3 receptor blockade to antipsychotic efficacy has been difficult to assess.
[ 11 C]-( + )-PHNO is a recently developed dopamine D 2/3 radioligand (Wilson et al, 2005) that is strongly D 3 preferring (Narendran et al, 2006) . In vivo imaging in non-human primates and mouse autoradiography paradigms have demonstrated that PHNO binding in the midbrain dopamine nuclei (substantia nigra, ventral tegmental area, SN/VTA) is almost completely due to D 3 binding (Rabiner et al, 2009) . [ 11 C]-( + )-PHNO binding also displays vulnerability to competition by selective D 3 agents in other D 3 -rich brain regions such as globus pallidus (GP), and ventral striatum (VST) (Narendran et al, 2006; Rabiner et al, 2009; Searle et al, 2010) . These findings suggest that the D 3 -preferring ligand [ Extensive preclinical data suggest that many antipsychotic medications bind to D 2 receptors with moderately higher affinity than they do to D 3 receptors (Table 1) (Levant, 1997; Schotte et al, 1996) . On the basis of these in vitro selectivity ratios, predicted occupancy of D 3 at therapeutic doses would be lower than D 2 occupancy, but still non-negligible (Table 1) . However, D 3 -binding levels by antipsychotics were called into question by a recent study by GraffGuerrero et al (2009) 
SUBJECTS AND METHODS

Subjects
Three adult male baboons were scanned in the test-retest study (baboons A, B, and C, papio Anubis, 20.1±4.8 kg) and antipsychotic studies (baboons B, C, and D, papio anubis, 23.9 ± 2.4 kg; Table 2 ). A minimum of 12 days was allowed between each experimental day for each baboon and no baboon was studied more than three times per month. Study procedures were approved by the Institutional Animal Care and Use Committees (IACUC) of Columbia University and the New York State Psychiatric Institute. (Levant, 1997; Schotte et al, 1996) The Test scans from the test-retest Study for these two subjects were included among the baseline scans in the Antipsychotic Study. For subjects A, B, and C, the test and retest scans were performed on the same day (that is, the same scanning session). All other scans were obtained on separate days (that is, single scan sessions). Each subject was given at least 12 days in between scanning sessions, and no subject was scanned more than three times in a month.
Test-Retest Study
To detect a potential mass-carryover effect at the D 3 site, three baboons were scanned at baseline and then 172 ± 36 min later (retest condition 52 ± 36 min after the end of the test scan; Table 2 ). The percent change in binding potential (see Data Analysis, below), DBP ND , was used as an outcome measure to assess reproducibility. This signed formulation was used rather than a measure of variability because the direction of change across conditions was the quantity of interest.
Antipsychotic Study
Baseline [ 11 C]-( + )-PHNO scans were acquired for each subject. Two baboons underwent three baseline scans and one baboon underwent two baseline scans ( Table 2 ). The average of each subject's baseline data was used for comparison with the drug challenge data. For challenge scans, each baboon received CLZ (0.5534 mg/kg) or HAL (0.0109 mg/kg), dissolved in 10 ml of saline vehicle. These doses were selected to attain target occupancies of 50% (CLZ) or 75% (HAL) in dorsal striatum where binding is predominantly to the D 2 receptors. Challenges were administered manually as a five-minute intravenous (iv) bolus, 15 min before the scan. Each subject underwent two scans following each drug. In all, 20 scans were acquired (eight baseline scans plus three subjects * two drugs * two post-challenge scans per drug).
Radiochemistry
[
11 C]-( + )-PHNO was prepared as described by Wilson et al (2005) , with some modifications (Rabiner et al, 2009 ).
PET Procedures
Fasted animals were initially immobilized with ketamine (10 mg per kg i.m.). Anesthesia during preparation and scans was maintained with 2% isoflurane via endotracheal tube. An iv catheter was inserted for radioligand administration, drug administration and hydration. An arterial catheter was placed in a femoral artery for arterial blood sampling and continuous blood pressure monitoring. Vital signs (blood pressure, pulse, EKG, temperature, pulse oximetry, and respiration) were monitored continuously using a patient monitoring system (DataScope Corp, Paramus, NJ) and remained within normal parameter ranges during all studies that did not include the administration of CLZ. Subjects' blood pressures did decrease by B20% during administration of CLZ. In all cases, hemodynamic parameters normalized with gentle administration of normal saline. No subject demonstrated other abnormalities in vital signs or EKG or required resuscitative measures. Temperature was maintained at 371C with a heated water blanket. All scanning was performed on an HR + scanner (Siemens, Knoxville, TN), operating in 3D mode. The animal's head was placed in the center of the field of view. A 10-min transmission scan was acquired before tracer injection for attenuation correction. [
11 C]-( + )-PHNO was administered as a 30 s iv bolus. Emission data were binned into a sequence of frames of increasing length.
Each scan included 22 frames (4 Â 15 s, 2 Â 1 min, 4 Â 2 min, 2 Â 5 min, and 10 Â 10 min). Total scan durations were 121 min. PET data were corrected for attenuation, scatter, and randoms and reconstructed using filtered back-projection with a Shepp filter (cutoff 0.5 cycles/ ray).
Arterial plasma samples were collected using an automated sampling system during the first 4 min (11 samples), and manually thereafter at longer intervals. A total of 22 arterial samples were collected for input function measurement. Six additional samples were collected during each scan for HPLC analysis of the unmetabolized fraction of radiotracer. Aliquots were also removed from six of the obtained samples for analysis of CLZ and HAL plasma levels.
Data Analysis
Plasma data. Arterial plasma input functions were formed as described previously (Abi-Dargham et al, 2000) . Briefly, centrifugation was performed to separate plasma from whole blood and activity in plasma was counted on a gamma counter (Wallac 1480, Perkin-Elmer, Boston MA). The unmetabolized fraction of radioligand was measured in the six samples taken for this analysis by HPLC using a fraction collection method. The measured fractions were fitted to a sum of two exponential functions. Whole-blood activity was multiplied by this parent-fraction curve to obtain an empirical estimate of the unmetabolized radiotracer concentration in arterial plasma. The empirical curve was fitted to a sum of three exponentials starting at the time of peak concentration. This modeled curve was used as the input function for compartment analysis. Peripheral clearance of radiotracer (L/hr) was computed as the injected activity divided by the area under the curve of the input function. Additionally, fp, the fraction of unmetabolized radiotracer not bound to plasma proteins, was measured with an ultrafiltration technique as previously described (Ekelund et al, 2007) . For fp measurement, a small quantity of [ 11 C]-( + )-PHNO was added to a sample of arterial plasma collected before radiotracer administration.
PET data. Decay-corrected reconstructed data were coregistered to T1 weighted anatomical MRIs acquired for each animal, using maximization of mutual information as implemented in the SPM2 software environment (Friston et al, 1995) . Regions of interest (ROIs) were drawn on the MRIs and transferred to the co-registered PET images. ROIs included putamen (PUT), caudate (CAU), VST, GP, SN/ VTA, and thalamus (THA). Time activity curves were generated from the mean activity in each region and each frame. Data were fitted using a two-tissue compartment model (2TC) with arterial plasma input, with cerebellum as reference region. The total distribution volume (VT) was computed in each region including cerebellum, and BP ND , the binding potential relative to the non-displaceable compartment (Innis et al, 2007) , was computed as: where ED 50 (*) is the estimated dose at which 50% of receptor type * is occupied by drug. Equation (4) follows from the rearrangement of the equilibrium mass action law for reversibly binding ligands (Equation (5)) OccðÃÞ ¼ Dose Dose þ ED 50 ðÃÞ ð5Þ
RESULTS
Test-Retest Study
The scan parameters for the test-retest study are shown in Table 4 . There were no significant differences between the baseline and retest conditions on any scan parameter.
Regional BP ND and DBP ND values are presented in C]-( + )-PHNO binding potential decreased purely from an order effect, suggesting the possibility that use of pre-and post-antipsychotic challenge scans from the same scanning session would introduce a quantification artifact. Therefore, in the subsequent antipsychotic occupancy study, only one antipsychotic challenge scan was acquired per session without baseline, thereby avoiding any possible mass carryover or other order effect from scanning twice in the same session. To measure the change across conditions, BP ND obtained from each antipsychotic challenge scan was individually compared with an average of previous baseline scans for the same subject, maintaining the within-subject design of this study.
Antipsychotic Study
The scan parameters for the Antipsychotic Study are shown in Table 6 . There were no significant differences on any scan parameter across all conditions.
Plasma input functions and time activity curves from several brain regions, averaged across all scans before and after administration of 0.5534 mg/kg of CLZ and 0.0109 mg/kg of HAL, are shown in Figure 1a and b. Representative BP ND maps from one subject across all conditions are shown in Figure 2 . Regional BP ND values at baseline and after administration of CLZ and HAL are shown in Table 7 . Both CLZ and HAL decreased [
11 C]-( + )-PHNO to an extent that was close to the target level in the dorsal striatum (44% decrease for CLZ, 70% decrease for HAL, Table 7 ). 
DISCUSSION
This study used [
11 C]-( + )-PHNO to investigate whether acute doses of the antipsychotic medications CLZ and HAL bind in vivo to the D 3 receptor and to estimate their D 2 : D 3 receptor selectivities. We observed that acute doses of HAL bind to D 3 receptors within the range predicted by in vitro data, and that CLZ does bind to D 3 receptors at the lower end of the range predicted by in vitro data. DBP ND in dorsal striatum (PUT, CAU), which is attributable mostly to D 2 occupancy, was similar to the clinical range for both drugs (that is, B45% for CLZ and B70% for HAL). DBP ND was lower in D 3 -rich regions, but measurable, as most clearly illustrated in the SN/VTA region, where [ Graff-Guerrero et al reported that chronically administered olanzapine, risperidone, and CLZ in patients with schizophrenia did not occupy D 3 , and that in some cases paradoxical increases in radioligand binding were observed (Graff-Guerrero et al, 2009) . The data we report in this study show that both CLZ and HAL do bind to D 3 receptors when administered acutely to anesthetized primates; this suggests that the observation in patients could be attributable to some other phenomenon such as upregulation of receptors following chronic administration, as discussed by the authors. The regulation of D 3 expression has been shown to be distinct from that of D 2 in a number of ways (Sokoloff et al, 2006) , and currently there is insufficient evidence either corroborating or ruling out the upregulation scenario. Another difference between the studies is the use of anesthesia in this study. Although it has been shown that isoflurane anesthesia can cause alterations in PET measurements of stimulant-induced dopamine release (Tsukada et al, 2002) , we are not aware of studies that have examined the effect of anesthesia on PET measurements of receptor occupancy by antipsychotic drugs, but this remains a possibility we cannot rule out. Additionally, our selectivity estimate used the assumption that the fractions of [ 11 C]-( + )-PHNO binding to D 2 and D 3 receptors in this cohort were similar to those measured in our previous studies with D 3 -selective agents. Although we have found these parameters to be consistent across subjects, we did not measure them directly in this study.
However, there are other methodological differences between the studies that could offer a simpler explanation for the differing conclusions. We used arterial plasma-based kinetic models following 120 min of emission data, while in the Graff-Guerrero study the authors used reference region analysis (SRTM, Lammertsma and Hume, 1996) following 90 min of data acquisition. The arterial-based method is a direct implementation of the equations of the 2TC model, whereas the SRTM algorithm is derived from the 2TC equations with additional simplifying assumptions. Although these two methods give correlated estimates of BP ND for many ligands, they are not identical, and can be quite different in cases where the data do not conform well to the simplifying assumptions of SRTM . We measured modest decreases in GP [ 11 C]-( + )-PHNO binding following CLZ (21 ± 14%) that still, however, included a component of binding of CLZ to D 3 . It is possible that these relatively modest decreases were difficult to detect with shorter scans and SRTM in this brain region where [ 11 C]-( + )-PHNO has complex kinetics, and especially slow washout. To test this, we reexamined our data under three additional conditions: the same analysis as before with data truncated to 90 min, and SRTM with both 90 and 120-min data. With the plasma-based approach, baseline binding measures were nearly identical at both durations in the D 2 -dominated dorsal striatum (90 min BP ND ¼ 100±5% of 120 min BP ND in caudate and 103±2% of 120 min BP ND in putamen), whereas in the D 3 -rich regions the binding measures tended to be decreased following truncation (90 min BP ND ¼ 94 ± 8% of 120 min BP ND in GP, 92±7% in VST, 91±4% in thalamus, 93 ± 4% in SN/VTA). With 120 min SRTM BP ND , the ratio to plasma-based BP ND decreased as a function of binding magnitude (Figure 3) , and this effect was even more pronounced with 90-min SRTM BP ND (Figure 3) . When the occupancy model was applied to 120-min SRTM data, D 2 : D 3 selectivity was 3.6 for HAL but increased to 19 for CLZ. When applied to 90-min data, selectivity was 3.7 for HAL and 49 (that is, nearly undetectable) for CLZ. Thus in these data at least, there was a pronounced qualitative difference in outcome associated with both scan duration and method of analysis, suggesting the longer duration with 2TC may be a more sensitive and reliable approach in this setting. It remains to be seen if a similar relationship is observable in data acquired in human subjects; our data in this study highlight the importance of comparing the different approaches in that setting. In rat brains, McCormick et al observed that CLZ, HAL, olanzapine, and risperidone all competed robustly with [ brain regions including the D 3 -rich cerebellar lobes 9 and 10 and the ventral pallidum, but were much less competitive in the setting of ex vivo autoradiographic measurements of [ 3 H]-( + )-PHNO binding in rats treated with the same drugs and then killed at 1 h after radioligand injection (McCormick et al, 2010) . In particular, it was observed that average HAL occupancy in the dorsal striatum (mostly attributable to D 2 ) was 80%, whereas occupancy in cerebellar lobes 9 and 10 (mostly D 3 ) was negligible, in contrast to our data where HAL exhibited robust D 3 binding (D 2 : D 3 selectivity ratio ¼ 2.38). The CLZ results from the two studies, on the other hand, are much more consistent with each other. In addition to species differences, the kinetic methods used in the two studies were different; the ex vivo occupancy estimates in the rodent study were based on tissue ratios of [ (Beaver et al, 2009) . These facts, however, seem unlikely by themselves to explain why no binding by the high affinity drug HAL was observed in the D 3 -dominated cerebellar lobes, whereas the lower affinity drug CLZ displayed moderate binding in those regions in rodents.
In this study, the D 2 : D 3 selectivity ratio for CLZ was slightly higher than that predicted by in vitro literature. One possible explanation for the lower than expected in vivo D 3 binding of CLZ observed here following a single iv dose may be a kinetic effect related to its fast off-rate (Seeman, 2002) . Kapur and Seeman measured in vitro on and off rates separately for a large number of antipsychotics in homogenates prepared from rat striatum and observed that there was much greater variability in k off than k on between drugs, and that k off therefore accounted for most of the observed affinity differences between drugs (Kapur and Seeman, 2000) . The ratio of CLZ k on to HAL k on was 1.4, whereas that of CLZ k off to HAL k off was 81, accounting for most of their affinity difference. These differences, and the fact that plasma clearance of CLZ and HAL following iv injection are similar (Cheng et al, 1988; Kudo and Ishizaki, 1999) , suggest that, following a bolus administration, CLZ will dissociate from receptors in response to decreasing plasma concentration much more rapidly than HAL. Receptor occupancy measured during a radiotracer scan (combined D 2 and D 3 occupancy in this case) is a weighted average of the occupancy over the course of the scan with weight at time t proportional to the concentration of the non-displaceable component (free plus nonspecifically bound) of the radioligand concentration (Endres and Carson, 1998; Kegeles et al, 2008) . Compared with dorsal striatum, the slower washout of [ 11 C]-( + )-PHNO from D 3 -rich regions, Figure 2 [ 11 C]-( + )-PHNO BP ND maps in one baboon at the level of the GP across the three conditions. Images are the average of three baseline scans and two post-drug scans for each antipsychotic, and were generated at each voxel with the SRTM algorithm. Abbreviations: GP, globus pallidus; SN/VTA, substantia nigra/ventral tegmental area; VST, ventral striatum. Baselines are averages of three scans (two subjects) or two scans (one subject). Post-drug scans are average of two scans per drug for every subject. DBP ND for each subject is relative to the average of that subject's baseline BP ND .
SRTM 120 min BP Figure 3 Scatter plots of regions of interest (ROI) analysis using SRTM. The left panel shows SRTM-derived BP ND using the full 120 min of data plotted against 2TC-derived BP ND . The graph shows that there is a similar proportionality between methods across moderate-binding regions, but not in high-binding regions. In the right panel, SRTM-derived data using 90-min truncated data are plotted against SRTM-derived data using 120 min of data. The graph shows the measures are virtually identical in the moderate-binding regions, but that the decrease in high-binding regions (relative to 2TC) is more pronounced with the truncated data. The solid line in each graph is the line of identity.
especially in the GP, might have caused the measured occupancy to be weighted more towards later times in the scan when CLZ occupancy may have decreased. This effect would be less pronounced for HAL because of its higher affinity and slower off-rate. The presence of this effect in these data is conjectural, but could be tested by administration of CLZ as a constant infusion rather than as a bolus.
In conclusion, we observed that acute doses of both CLZ and HAL bind to D 3 receptors in vivo. HAL binds to D 3 receptors within the range predicted by in vitro data and CLZ binds to D 3 receptors at the lower end of the range predicted by in vitro data. These results suggest that antipsychotic medications do bind to D 3 receptors at predicted levels when administered acutely in vivo, and that therefore the apparent lack of occupancy by antipsychotics, including CLZ, in D 3 -rich regions when administered chronically to patients, is due to some other phenomenon. We have highlighted some of the methodological issues that might have lead to discrepancies in estimates of occupancy in D 3 -rich regions between our report and previous reports. An alternative explanation that could reconcile our data and those of Graff-Guerrero et al would be the upregulation of D 3 receptors following chronic antipsychotic treatment. The regulation of D 3 expression has been shown to be distinct from that of D 2 in a number of ways (Sokoloff et al, 2006) , and additional studies are required to test the upregulation scenario. Future studies should address the effects of chronic administration on expression of D 3 and also assess the binding of other commonly used antipsychotic medications to D 3 receptors. This information will allow researchers a more complete understanding of the role of the D 3 receptor in the pathophysiology and treatment of schizophrenia, and therefore has great implications for the targeted development of novel therapeutics.
